T. Rowe Price Associates
CBIO

T. Rowe Price Associates’s Crescent Biopharma CBIO Stock Holding History

T. Rowe Price Associates’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Sell
275,581
-27,970
-9% -$546K ﹤0.01% 1573
2026
Q1 		$5.58M Sell
303,551
-34,574
-10% -$397K ﹤0.01% 1386
2025
Q4 		$4.01M Sell
338,125
-45,470
-12% -$579K ﹤0.01% 1475
2025
Q3 		$4.56M Buy
+383,595
New +$5.09M ﹤0.01% 1420
2019
Q3 		– Sell
-30,444
Closed -$36.3M – 2532
2019
Q2 		$36.3M Sell
30,444
-3,798
-11% -$4.54M 0.01% 988
2019
Q1 		$42.7M Sell
34,242
-384
-1% -$440K 0.01% 933
2018
Q4 		$32.8M Buy
34,626
+190
+0.6% +$229K 0.01% 975
2018
Q3 		$49.6M Sell
34,436
-39
-0.1% -$59K 0.01% 915
2018
Q2 		$55.6M Buy
34,475
+5,767
+20% +$9.92M 0.01% 853
2018
Q1 		$46.6M Buy
28,708
+16,058
+127% +$33.4M 0.01% 903
2017
Q4 		$21.2M Buy
12,650
+1,661
+15% +$2.2M ﹤0.01% 1168
2017
Q3 		$15.4M Sell
10,989
-2,639
-19% -$3.1M ﹤0.01% 1261
2017
Q2 		$15.2M Buy
+13,628
New +$11.3M ﹤0.01% 1240
2015
Q1 		– Sell
-913
Closed -$658K – 2555
2014
Q4 		$658K Buy
+913
New +$715K ﹤0.01% 1845

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates's CBIO Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Crescent Biopharma (CBIO) stake by 9.2% in Q2 2026, selling an estimated $546K and leaving 275,581 shares worth $4.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

T. Rowe Price Associates first reported a position in CBIO in Q4 2014 and has held it in 14 quarters since. The position peaked at $55.6M in Q2 2018. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • T. Rowe Price Associates held 275,581 shares of Crescent Biopharma worth $4.96M as of Q2 2026.
  • T. Rowe Price Associates sold 27,970 Crescent Biopharma shares in Q2 2026, an estimated $546K.
  • Crescent Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1573 holding.
  • T. Rowe Price Associates first reported a position in Crescent Biopharma in Q4 2014 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Crescent Biopharma position peaked at $55.6M in Q2 2018.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.